Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molibresib + Trametinib in SCLC and Ras-Mutated Tumors
NCT03266159Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Nov 2017
- Primary completion
- Aug 2020
- Modality
- Allosteric Modulators
01
Overview
A Phase 2 trial of molibresib in small cell lung cancer (SCLC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma (PDAC), solid tumor, sponsored by GSK. Planned start Nov 2017; status: withdrawn.
02
Drugs
molibresib
03
Conditions
small cell lung cancer (SCLC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)solid tumor
Beyond the preview
Go deeper on NCT03266159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03266159.